NCT04937153View on ClinicalTrials.gov

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Solid Tumor
Interventions
BIOLOGICAL

Acasunlimab

Acasunlimab will be administered intravenously (IV) once every 21 days.

BIOLOGICAL

Pembrolizumab

Pembrolizumab will be administered IV once every 21 days.

Trial Locations (2)

Unknown

National Cancer Center East, Chiba

National Cancer Center Hospital, Tokyo

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY

NCT04937153 - GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter